When India approved two vaccines, Covaxin and Covishield for the vaccination drive in January, several questions were raised about the efficiency of the Covaxin dose. In the initial days, people even refused to take Covaxin.
Covaxin was developed by Bharat Biotech based out of Hyderabad. People, those who have criticised Covaxin, include big names like the CEO of Serum Institute of India Adar Poonawalla.
In an interview in January this year, Adar Poonawalla said, three vaccines Pfizer-BioNTech, Modera, and Oxford-AstraZeneca have passed the scientific evaluations and can work effectively against the virus.
Without taking any names, the SII CEO said, other vaccines are like water and the effectiveness of them are yet to be evaluated. He later gave a clarification on the water-like comment row.
Now things have changed completely, Covaxin is in high demand now and people are showing interest in getting vaccinated with Covaxin. The vaccine dose has got global recognition and other countries are also showing their interest to get the supply of Covaxin.
The western countries like the United States, United Kingdom are showing their interest in procuring Covaxin vaccine doses, Bharat Biotech Chief Dr. Krishna Ella said. However, Bharat Biotech is giving utmost priority to India, despite the global demand for Covaxin.
Unlike Covishied, developed by Pune-based Serum Institute of India, less percentage of people who have taken Covaxin developed symptoms of fever and body patients, making it their favourite vaccine dose.